<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107921</url>
  </required_header>
  <id_info>
    <org_study_id>H-2107-210-1239</org_study_id>
    <nct_id>NCT05107921</nct_id>
  </id_info>
  <brief_title>Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy</brief_title>
  <official_title>Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the efficacy and safety of bromfenac sodium hydrate eye drops&#xD;
      in patients with familial exudative vitreoretinopathy receiving diode laser photocoagulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the presence of macular edema as the primary measure and the&#xD;
      presence of conjunctival injection as the secondary measure for the investigation of the&#xD;
      efficacy of bromfenac sodium hydrate eye drops in patients with familial exudative&#xD;
      vitreoretinopathy receiving diode laser photocoagulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular edema response rate</measure>
    <time_frame>4 weeks after the diode laser photocoagulation</time_frame>
    <description>Presence of macular edema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival injection response rate</measure>
    <time_frame>4 weeks after the diode laser photocoagulation</time_frame>
    <description>Presence of conjunctival injection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Familial Exudative Vitreoretinopathies</condition>
  <arm_group>
    <arm_group_label>Bromfenac sodium hydrate eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive bromfenac sodium hydrate eye drops twice daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromfenac Sodium</intervention_name>
    <description>The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.</description>
    <arm_group_label>Bromfenac sodium hydrate eye drops</arm_group_label>
    <other_name>Bronuck</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed patients with familial exudative vitreoretinopathy&#xD;
&#xD;
          -  Needing diode laser photocoagulation&#xD;
&#xD;
          -  Consent to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of corneal diseases&#xD;
&#xD;
          -  History of hypersensitivity to bromfenac sodium&#xD;
&#xD;
          -  History of hypersensitivity to non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Progressive ocular infection&#xD;
&#xD;
          -  Liver diseases&#xD;
&#xD;
          -  Hypersensitivity to sulfur dioxide&#xD;
&#xD;
          -  Receiving anti-coagulation drugs&#xD;
&#xD;
          -  History of coagulopathies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Hun Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong Hun Kim, MD, PhD</last_name>
    <phone>82-2-2072-3446</phone>
    <email>steph25@snu.ac.kr</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Hun Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Exudative Vitreoretinopathies</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromfenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

